XTL Biopharmaceuticals Ltd ADR is a biotechnology business based in the US. XTL Biopharmaceuticals Ltd ADR shares (XTLB) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.49 |
|---|---|
| 52-week range | $1.35 - $6.69 |
| 50-day moving average | $1.81 |
| 200-day moving average | $2.70 |
| Wall St. target price | $30.00 |
| PE ratio | 0 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.00 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.49 from 2022-07-01
| 1 week (2022-06-24) | -4.49% |
|---|---|
| 1 month (2022-06-03) | -13.37% |
| 3 months (2022-04-01) | -34.65% |
| 6 months (2022-01-03) | -48.26% |
| 1 year (2021-07-02) | -62.18% |
|---|---|
| 2 years (2020-07-02) | -6.42% |
| 3 years (2019-07-03) | 1.866 |
| 5 years (2017-07-03) | 3.39 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -9.4% |
| Return on equity TTM | 12.83% |
| Profit margin | 0% |
| Book value | $1.10 |
| Market capitalisation | $8.3 million |
TTM: trailing 12 months
We're not expecting XTL Biopharmaceuticals Ltd ADR to pay a dividend over the next 12 months.
XTL Biopharmaceuticals Ltd ADR's shares were split on a 1:5 basis on 9 February 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XTL Biopharmaceuticals Ltd ADR shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for XTL Biopharmaceuticals Ltd ADR shares which in turn could have impacted XTL Biopharmaceuticals Ltd ADR's share price.
Over the last 12 months, XTL Biopharmaceuticals Ltd ADR's shares have ranged in value from as little as $1.35 up to $6.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XTL Biopharmaceuticals Ltd ADR's is 1.0439. This would suggest that XTL Biopharmaceuticals Ltd ADR's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
XTL Biopharmaceuticals Ltd. , a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.